EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent R...

EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent R...

by Sano Genetics

Life & Natural Systems Chemistry PNChemistryPNNOrganic chemistry
🎙 Sano Genetics 👥 949 📅 August 27, 2026 ⏱ 41 min 👁 2 📄 expert opinion 🧭 2026-08-27
Available in: English (current) Français

Keywords

triangulationgenetic evidencedrug targetscollider biasherd psychology

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Dr. Brent Richards, a professor at McGill University and CEO of 5 Prime Sciences. They discuss the role of human genetics in drug discovery, emphasizing the importance of triangulating different types of genetic evidence to validate drug targets. Richards explains that while GWAS and Mendelian randomization are powerful, they have limitations and can be biased. He highlights the phenomenon of ‘herd psychology’ in target selection, where companies tend to follow popular targets rather than novel ones, and notes that the volume of literature on a target does not predict approval success. The conversation covers the failure of the Zeus IL-6 trial despite strong genetic evidence, illustrating how cytokine signaling can confound Mendelian randomization. Richards describes what constitutes a ‘gold standard’ genetic evidence package, including susceptibility vs. progression genetics, and the need for diverse genomes. He shares a personal story of a diabetes patient that motivated his work, and discusses the balance between academia and industry. The episode also touches on collider bias in genetically stratified trials and the importance of systematic pipelines for de-risking drug development.

187 words

Critical Evaluation

Value of the Information & Strength of the Argument

The episode provides valuable insights into the practical application of human genetics in drug discovery, going beyond simple checkboxes. Richards argues convincingly for the need to triangulate evidence from multiple sources to mitigate biases. He uses concrete examples, such as the Zeus IL-6 trial and the SGLT2 target, to illustrate complex concepts. The discussion on herd psychology and the null effect of literature volume on approval success is particularly thought-provoking, challenging common industry practices. The argumentation is solid, though it relies on anecdotal evidence and personal experience rather than systematic data presentation.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with Richards referencing specific studies and methods, such as Mendelian randomization and GWAS. He mentions a paper on MS susceptibility vs. progression and a Regeneron paper on triglycerides, but does not provide full citations. The description includes a link to 5 Prime Sciences’ symposium, which is a relevant source for further information. The title accurately reflects the content, focusing on triangulating genetic evidence and avoiding bias. The podcast is well-structured with clear chapters, and the discussion stays on topic.

191 words

Title / Content Match

The title accurately reflects the core themes of the episode: triangulating genetic evidence and avoiding bias in drug target selection.

Quality & Reliability

8/10

The discussion is led by a professor of human genetics with extensive experience in both academia and industry. The content is well-structured, nuanced, and grounded in scientific reasoning, though it relies on anecdotal evidence and personal experience rather than systematic review.

Chapters

Cited Sources

Concurring Sources

  • 5 Prime Sciences Symposium 2026 — The symposium is directly relevant to the topics discussed, featuring experts on translating genetic evidence into drug development decisions.

Contribution & Novelties

The episode offers a nuanced perspective on the use of genetic evidence in drug discovery, emphasizing the importance of triangulation and the pitfalls of over-reliance on single methods. It provides a candid look at industry psychology and the challenges of novel target validation. The discussion on collider bias in clinical trials is particularly insightful.

Pour aller plus loin :

  • Mendelian randomization — A key method discussed for causal inference in drug target validation.
  • Genome-wide association study — The foundational tool for identifying genetic variants associated with diseases.
  • Collider bias — A bias that can distort results in genetically stratified trials, as discussed in the episode.
  • Zeus trial IL-6 — The clinical trial mentioned as a failure despite strong genetic evidence.

120 words

Radar Profile

The radar profile shows high scores across all dimensions, indicating a well-rounded and reliable episode. The high 'quantite_information' and 'qualite_information' scores reflect the depth and quality of the discussion, while the 'niveau_technique' score indicates a technical but accessible level. The 'fiabilite_globale' score is high, supported by the speaker's expertise and the use of concrete examples.

Reliability 8/10